Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sarilumab extension study in active rheumatoid arthritis on background DMARDs
NL-OMON41668Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sarilumab in rheumatoid arthritis (RA), sponsored by Sanofi. Primary endpoint: Safety assessment of sarilumab over time. Started Apr 2014; status: active, not recruiting.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON41668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41668.